- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators
- Follicle Stimulating Hormones
- Dopamine Agonists
- Metformin Hydrochloride
Female Fertility Drugs Market size valued at USD 3.48 billion in 2022 is expected to reach USD 5.35 billion in 2028, at a CAGR of 6.3% from 2023-2029. Female fertility drugs are the agents used to improve reproductive health in women and act to stimulate the follicle development of the ovary. Women's fertility drugs are extremely effective and the first treatment option to overcome infertility. Fertility drugs act by direct stimulation of ovaries or balancing the hormone levels. Infertility in women occurs due to hypothalamic dysfunction, excessive prolactin, pelvic inflammatory diseases, premature ovarian insufficiency, and polycystic ovary syndrome among others. The major symptom associated with infertility is an absence or irregular menstrual cycle. The female fertility drugs market is growing at a significant CAGR with several local and international players operating in infertility treatment.
The prevalence of infertility is increasing due to changes in lifestyles such as smoking and alcohol consumption. According to World Health Organization, approximately 60-80 Mn couples are suffering from infertility around the world. Moreover, acquisitions & mergers, collaborations, product approvals, and product launchings are the strategies followed by the companies for increasing their market revenue share in the female fertility drugs market. For instance, in March 2014, Ferring Pharmaceuticals received FDA approval for the combination of Menopur and Bravelle injection used in the treatment of infertility.
Fastest Growing Market
Increase in the female population, rise in prevalence of infertility condition due to change in lifestyle, government initiation for the infertility management, rise in disposable income are anticipated to fuel the women fertility drugs market over the forecast period. Moreover, increase in R&D activities for the development of new drugs to overcome the infertility, rise in the prevalence of obesity, and increase in the maternal age are expected to boost the women fertility drugs market. However, stringent regulatory policies for drug approvals, lack of awareness about women fertility drugs in underdeveloped countries, and alternative infertility treatments such as in vitro fertilization are expected to restrain the growth of women fertility drugs market over the forecast period.
The Female fertility drugs market size was valued at USD 3.48 billion in 2022.
The Female fertility drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Female fertility drugs market key players are Sanofi S.A. (France), Merck KGaA (Germany), Novartis AG (Switzerland), Ferring B.V. (Switzerland), Berlex Laboratories Inc. (U.S.), Eli Lilly and Co. (U.S.), Serono Inc. (U.S.), Novogyne Pharmaceuticals (U.S.), Pfizer, Inc. (U.S.)